LOC644695 Inhibitors

LY294002 and U0126, which target the PI3K/Akt and MAPK/ERK pathways respectively, pivotal for regulating cell growth and survival. By inhibiting PI3K, LY294002 disrupts subsequent Akt signaling, altering the regulation of proteins downstream of this pathway. Similarly, U0126 impedes the MEK1/2 kinases, thereby stalling the MAPK/ERK signaling and affecting proteins linked to this route. Rapamycin latches onto the mTOR complex, a central player in cell growth control, and thus can influence proteins that are part of the mTOR signaling network. PP2, by inhibiting Src family kinases, modulates cell adhesion and angiogenesis, thereby impacting proteins that are entwined in these pathways.

Nutlin-3, by disrupting the MDM2-p53 interaction, affects the multitude of proteins that are regulated by the p53 pathway, known for its role in cellular stress responses. SP600125 puts a halt to JNK activity, potentially altering the function of proteins that are associated with stress responses. SB431542 inhibits the TGF-β receptor, modifying the TGF-β signaling pathway and influencing the roles of proteins involved in this path. ZM-447439 disrupts cell division by inhibiting Aurora kinases, affecting proteins that are crucial for mitotic progression. Moreover, Leflunomide hampers pyrimidine biosynthesis by inhibiting dihydroorotate dehydrogenase, which can impact the synthesis and function of proteins reliant on nucleotides. Imatinib, a tyrosine kinase inhibitor, adjusts cell proliferation signaling, impacting associated proteins. Olaparib, a PARP inhibitor, affects proteins involved in DNA damage response. Bortezomib, by inhibiting the proteasome, affects the degradation of proteins that are crucial in cell cycle control and signal transduction, thereby potentially influencing protein stability and function within these pathways.